Tags: Arthritis | Chronic Pain | rheumatoid | arthritis | drug | biosimilar | amgen

FDA OKs Amgen Version of Rheumatoid Arthritis Drug

Hands afflicted with rheumatoid arthritis.
A man with rheumatoid arthritis shows the condition of his hands at his home in Derry, Pennsylvania, earlier this year.

Tuesday, 10 December 2019 09:56 AM

 The Food and Drug Administration (FDA) on Friday approved Amgen Inc.'s biosimilar copy of Johnson & Johnson's blockbuster rheumatoid arthritis drug, Remicade, according to the regulator's website.

The biosimilar, Avsola, has the same chemical components, dosage form and strength as Remicade and would treat a range of autoimmune disorders.

Amgen did not give the pricing of the drug, but said is confident about being competitive in the biosimilar market.

The label for the treatment carries a boxed warning, FDA's harshest, flagging risks of serious infections and malignancy, similar to that of Remicade's.

With the regulatory approval, Avsola joins the existing biosimilars to J&J's drug, including Pfizer's 2017 approved Ixifi, Celltrion Inc.'s Inflectra and Merck & Co. and Samsung Bioepis Co. Ltd.'s Renflexis.

Avsola will add to Amgen's growing biosimilar unit, which could have a value of $2 billion over the next several years, says Jefferies analyst Michael Yee.

However, Yee doesn't see the drug as a major driver of sales for Amgen right now.

Avsola was approved for all eligible indications of Remicade, including bowel disease, Crohn's disease and skin disorder plaque psoriasis, the agency said.

Biosimilars are medicines considered highly similar to an original drug and are cheaper alternatives to biologic products.

The blockbuster drug Remicade, approved in the United States, European Union and other regions, has steadily lost market share among patients enrolled in the Canadian province of Quebec's public drug program and elsewhere, where biosimilars have been slowly catching on with doctors and patients.

Remicade brought in sales of $1.14 billion in the third quarter, diwn 17.6% from last year. 

© 2020 Thomson/Reuters. All rights reserved.

   
1Like our page
2Share
Health
The Food and Drug Administration (FDA) on Friday approved Amgen Inc.'s biosimilar copy of Johnson & Johnson's blockbuster rheumatoid arthritis drug, Remicade, according to the regulator's website. The biosimilar, Avsola, has the same chemical components, dosage form and...
rheumatoid, arthritis, drug, biosimilar, amgen
263
2019-56-10
Tuesday, 10 December 2019 09:56 AM
Newsmax Media, Inc.
 

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
America's News Page
© Newsmax Media, Inc.
All Rights Reserved